BioSpace

Poplar Therapeutics Closes $45 million Series A Extension to Advance Development of Lead Program, PHB-050, A New Class of Anti-IgE Therapy for Multiple Atopic Conditions

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Poplar Therapeutics, Inc., a clinical-stage immunology company developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions, today ...
The Lancet

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label ...

gDepartment of Surgery, Division of Surgical Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA hDepartment of Internal Medicine, Division of Hematology and Oncology, The ...
story-cars

1955 NAMI-050 “Belka” (Squirrel)

NAMI, a leading institution for automotive research in Russia, has a century-long history of significant contributions to Soviet car design, including the first Soviet-made car, NAMI 1. Amid the ...
Cancer Research

Abstract 5215: MOA study of KD050, an anti-PD-1/IL-15 bi-functional antibody selectively targeted PD-1 positive tumor-infiltrating lymphocytes resulted in robust anti-tumor ...

1Kadmon Corporation LLC, New York, NY.